SCHEMBL6255773

SCHEMBL6255773

O=C(Nc1nc(-c2ccc(Cl)cc2)cs1)C1CCCC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.70
MAPT P10636 4/20 0.70
LMNA P02545 2/20 0.70
HTT P42858 2/20 0.70
ALOX12 P18054 1/20 0.70
MAPK1 P28482 1/20 0.70
RAB9A P51151 6/20 0.69
ABL1 P00519 2/20 0.67
NPC1 O15118 3/20 0.64
ALDH1A1 P00352 3/20 0.64
POLB P06746 1/20 0.64
NFKB1 P19838 1/20 0.64
NFKB2 Q00653 1/20 0.64
RELA Q04206 1/20 0.64
KDM4E B2RXH2 1/20 0.64
GSTO1 P78417 1/20 0.61
ADORA3 P0DMS8 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15688795 0.99 SMN1; SMN2 (0.72) SMN1; SMN2MAPTLMNAHTTALOX12
SCHEMBL15689170 0.95 ABL1 (0.74) SMN1; SMN2MAPTLMNAHTTALOX12
SCHEMBL2554299 0.89 ABL1 (0.67) SMN1; SMN2MAPTLMNAHTTALOX12
SCHEMBL3339276 0.88 MAPT (0.61) SMN1; SMN2MAPTLMNAHTTALOX12
SCHEMBL17107238 0.86 RAB9A (0.70) SMN1; SMN2MAPTLMNAHTTRAB9A
SCHEMBL2753301 0.85 LMNA (0.71) SMN1; SMN2MAPTLMNAHTTRAB9A
SCHEMBL13257017 0.83 LMNA (0.62) SMN1; SMN2MAPTLMNAHTTALOX12
SCHEMBL10808572 0.82 MEN1 (0.82) SMN1; SMN2MAPTLMNAHTTALOX12
SCHEMBL10924496 0.82 ABL1 (0.78) SMN1; SMN2MAPTLMNAHTTALOX12
SCHEMBL14758306 0.81 KDM4E (0.70) SMN1; SMN2MAPTLMNAHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2945936-A1 THIAZOLE DERIVATIVES AS ALPHA 7 NACHR MODULATORS Lupin Limited (IN) 2015-11-25 EP disclosed
US-20150299178-A1 Thiazole Derivatives as Alpha 7 NACHR Modulators LUPIN LIMITED (IN) 2015-10-22 US disclosed
WO-2014072957-A1 THIAZOLE DERIVATIVES AS ALPHA 7 NACHR MODULATORS LUPIN LIMITED (IN) 2014-05-15 WO disclosed
US-6900219-B2 ABCA-1 elevating compounds CV THERAPEUTICS, INC. (US) 2005-05-31 US disclosed
EP-1513534-A2 COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2005-03-16 EP disclosed
US-20030220356-A1 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2003-11-27 US disclosed
WO-2003084544-A2 COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220356-A1 ABCA-1 elevating compounds ABCD3, ABCE1, ABCB4 SMN1; SMN2 4558/4885MAPT 4100/4885LMNA 1603/4885
US-20150299178-A1 Thiazole Derivatives as Alpha 7 NACHR Modulators CHRNA7, CHRM1, CHRM2 SMN1; SMN2 1298/4885MAPT 61/4885LMNA 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.